Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials


In the original manuscript, there were errors within the legends of Figure 1B and Figure 3B.

Figure 1B. Kaplan-Meier curve for OS for patients with EGFR mutation:
- 95% CI for HR should be [0.596, 1.538], however, the figure in the paper reads [0.542, 1.538]
- The 2-sided P-value should be 0.861, however, the figure in the paper reads 0.651

Figure 3B. Kaplan-Meier curve for OS for patients with EGFR exon 19 mutation:
- 95% CI for HR should be [0.366, 1.412], however, the figure in the paper reads [0.356, 1.412]
- The 1-sided P-value should be 0.169, however, the figure in the paper reads 0.189